Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines
Conditions
Interventions
Botulinum Toxin Type A
Placebo
Locations
8
United States
Private practice
Birmingham, Alabama, United States
Private practice
Mobile, Alabama, United States
Private practice
San Diego, California, United States
Private practice
Englewood, Colorado, United States
Private practice
Aventura, Florida, United States
Private practice
Nashville, Tennessee, United States
Start Date
September 1, 2014
Primary Completion Date
November 1, 2014
Completion Date
May 1, 2015
Last Updated
August 26, 2022
NCT05481931
NCT03985982
NCT06411002
NCT05146999
NCT05894109
NCT05148000
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions